Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00324740 · ClinicalTrials.gov registry record · Phase 1
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00324740: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00324740 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00324740, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects and best dose of isotretinoin when given together with vorinostat and to see how well they work in treating patients with advanced kidney cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Isotretinoin may cause kidney cancer cells to look more like normal cells, and to grow and spread more slowly. Giving vorinostat together with isotretinoin may kill more tumor cells.
Interventions
- DRUG vorinostat
- DRUG isotretinoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-03 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00324740
The ClinicalTrials.gov registry entry for NCT00324740 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vorinostat is the first listed.
NCT00324740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00324740 about?
NCT00324740 is a clinical study titled "Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer". This phase I/II trial is studying the side effects and best dose of isotretinoin when given together with vorinostat and to see how well they work in treating patients with advanced kidney cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. I...
What is the current status of trial NCT00324740?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2006-03. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00324740?
The interventions under investigation include: vorinostat (DRUG), isotretinoin (DRUG).
Who is sponsoring clinical trial NCT00324740?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.